Schroder Investment Management Group
MLYS icon

Schroder Investment Management Group’s Mineralys Therapeutics MLYS Stock Holding History

Schroder Investment Management Group’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.07M Hold
130,592
– – ﹤0.01% 856
2025
Q4 		$4.64M Buy
+130,592
New +$5.24M ﹤0.01% 758
2025
Q2 		– Sell
-62,893
Closed -$922K – 1219
2025
Q1 		$922K Buy
+62,893
New +$723K ﹤0.01% 1004

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $231M AUM 83.19% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Schroder Investment Management Group's MLYS Position: Q1 2026 in Review

Schroder Investment Management Group held its Mineralys Therapeutics (MLYS) position steady in Q1 2026 at 130,592 shares worth $3.07M. The position accounts for ﹤0.01% of the portfolio, ranked #856.

Schroder Investment Management Group first reported a position in MLYS in Q1 2025 and has held it in 3 quarters since. The position peaked at $4.64M in Q4 2025. 214 funds tracked by Wall St. Rank hold MLYS as of Q1 2026.

  • Schroder Investment Management Group held 130,592 shares of Mineralys Therapeutics worth $3.07M as of Q1 2026.
  • Schroder Investment Management Group left its Mineralys Therapeutics share count unchanged in Q1 2026.
  • Mineralys Therapeutics made up ﹤0.01% of Schroder Investment Management Group's portfolio in Q1 2026, its #856 holding.
  • Schroder Investment Management Group first reported a position in Mineralys Therapeutics in Q1 2025 and has held it in 3 quarters since.
  • Schroder Investment Management Group's Mineralys Therapeutics position peaked at $4.64M in Q4 2025.
  • 214 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q1 2026.

Based on Schroder Investment Management Group's 13F filing for Q1 2026, filed 14 May 2026.